BACKGROUND: A significant number of medulloblastomas (MBs) originate from abnormal activation of the sonic hedgehog/patched (SHH/PTC) signaling pathway. Although p53 deficiency enhances tumor formation in mice, inactivation of the p53 gene is seen in a minority of MBs. Wild-type p53-induced phosphatase 1 (WIP1) downregulates p53 expression and has been shown to be overexpressed in MBs. OBJECTIVE: We tested the hypothesis that overexpression of WIP1 enhances tumor formation in an SHH-dependent model of MB. METHODS: We used the RCAS/Ntv-a system to study the effect of WIP1 in vitro and in vivo. We transfected A375-TVA cells with RCAS-WIP1 and then exposed these cells to cisplatin to determine the effect on p53 expression. We modeled ectopic WIP1 expression independently and in combination with SHH in the cerebella of newborn mice to assess the effect on tumor formation. Mice were observed for 12 weeks or until neurological symptoms developed. The brains were examined for tumor formation. RESULTS: A375-TVA cells infected with RCAS-WIP1 demonstrated reduced p53 expression after exposure to cisplatin compared with controls. We detected tumors in 12 of 35 mice (34%) injected with RCAS-WIP1 and RCAS-SHH. Tumors were detected in 3 of 40 mice (8%) injected with RCAS-SHH alone. The difference in tumor formation rates was significant (χ(2) test, P = < .01). Tumors did not form in mice injected with RCAS-WIP1 alone. CONCLUSION: We show that ectopic expression of WIP1 cooperates with SHH to enhance formation of MB, although it is insufficient to induce tumors independently. Our results verify the role of WIP1 in MB formation and provide a crucial link to the inactivation of p53 in MBs.
BACKGROUND: A significant number of medulloblastomas (MBs) originate from abnormal activation of the sonic hedgehog/patched (SHH/PTC) signaling pathway. Although p53 deficiency enhances tumor formation in mice, inactivation of the p53 gene is seen in a minority of MBs. Wild-type p53-induced phosphatase 1 (WIP1) downregulates p53 expression and has been shown to be overexpressed in MBs. OBJECTIVE: We tested the hypothesis that overexpression of WIP1 enhances tumor formation in an SHH-dependent model of MB. METHODS: We used the RCAS/Ntv-a system to study the effect of WIP1 in vitro and in vivo. We transfected A375-TVA cells with RCAS-WIP1 and then exposed these cells to cisplatin to determine the effect on p53 expression. We modeled ectopic WIP1 expression independently and in combination with SHH in the cerebella of newborn mice to assess the effect on tumor formation. Mice were observed for 12 weeks or until neurological symptoms developed. The brains were examined for tumor formation. RESULTS:A375-TVA cells infected with RCAS-WIP1 demonstrated reduced p53 expression after exposure to cisplatin compared with controls. We detected tumors in 12 of 35 mice (34%) injected with RCAS-WIP1 and RCAS-SHH. Tumors were detected in 3 of 40 mice (8%) injected with RCAS-SHH alone. The difference in tumor formation rates was significant (χ(2) test, P = < .01). Tumors did not form in mice injected with RCAS-WIP1 alone. CONCLUSION: We show that ectopic expression of WIP1 cooperates with SHH to enhance formation of MB, although it is insufficient to induce tumors independently. Our results verify the role of WIP1 in MB formation and provide a crucial link to the inactivation of p53 in MBs.
Authors: Howard L Weiner; Richard Bakst; Marc S Hurlbert; Jason Ruggiero; Esther Ahn; Wing Shing Lee; Daniel Stephen; David Zagzag; Alexandra L Joyner; Daniel H Turnbull Journal: Cancer Res Date: 2002-11-15 Impact factor: 12.701
Authors: Trudy G Oliver; Tracy Ann Read; Jessica D Kessler; Anriada Mehmeti; Jonathan F Wells; Trang T T Huynh; Simon M Lin; Robert J Wechsler-Reya Journal: Development Date: 2005-04-20 Impact factor: 6.868
Authors: A Ehrbrecht; U Müller; M Wolter; A Hoischen; A Koch; B Radlwimmer; B Actor; A Mincheva; T Pietsch; P Lichter; G Reifenberger; R G Weber Journal: J Pathol Date: 2006-03 Impact factor: 7.996
Authors: Frank Mendrzyk; Bernhard Radlwimmer; Stefan Joos; Felix Kokocinski; Axel Benner; Daniel E Stange; Kai Neben; Heike Fiegler; Nigel P Carter; Guido Reifenberger; Andrey Korshunov; Peter Lichter Journal: J Clin Oncol Date: 2005-12-01 Impact factor: 44.544
Authors: H Avet-Loiseau; A M Vénuat; M J Terrier-Lacombe; A Lellouch-Tubiana; M Zerah; G Vassal Journal: Br J Cancer Date: 1999-04 Impact factor: 7.640
Authors: Leon F McSwain; Kiran K Parwani; Shubin W Shahab; Dolores Hambardzumyan; Tobey J MacDonald; Jennifer M Spangle; Anna Marie Kenney Journal: Front Oncol Date: 2022-06-07 Impact factor: 5.738
Authors: Paul A Northcott; David T W Jones; Marcel Kool; Giles W Robinson; Richard J Gilbertson; Yoon-Jae Cho; Scott L Pomeroy; Andrey Korshunov; Peter Lichter; Michael D Taylor; Stefan M Pfister Journal: Nat Rev Cancer Date: 2012-12 Impact factor: 60.716
Authors: J Wen; J Lee; A Malhotra; R Nahta; A R Arnold; M C Buss; B D Brown; C Maier; A M Kenney; M Remke; V Ramaswamy; M D Taylor; R C Castellino Journal: Oncogene Date: 2016-04-18 Impact factor: 9.867